Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. It also develops the Trident Artificial Intelligence (TAI) precision medicine platform which is used to identify biomarkers in its clinical programs to target a specific patient segment. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
No news articles found for Tharimmune.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
